
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 224 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic”, Eur J Prev Cardiol, 2021.
, “Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study”, Diabetes Care, 2021.
, “Safety of antidepressants in a primary care cohort of adults with obesity and depression”, PLoS One, vol. 16, p. e0245722, 2021.
, “Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes”, BMJ Open Diabetes Res Care, vol. 8, 2020.
, “Cardiovascular events and mortality in people with and without type 2 diabetes: An observational study in a contemporary multi-ethnic population”, J Diabetes Investig, 2020.
, “Comparative effectiveness of gliclazide modified release vs sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes”, Diabetes Obes Metab, 2020.
, “Incidence of Depression and First-Line Antidepressant Therapy in People with Obesity and Depression in Primary Care”, Obesity (Silver Spring), vol. 28, pp. 977-984, 2020.
, “Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study”, Lancet Diabetes Endocrinol, vol. 8, pp. 27-35, 2020.
, “Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study”, J Clin Transl Endocrinol, vol. 20, p. 100225, 2020.
, “Missed Opportunities for Timely Recognition of Chronic Limb-Threatening Ischaemia in Patients Undergoing a Major Amputation: A Population Based Cohort Study Using the UK's Clinical Practice Research Datalink”, Eur J Vasc Endovasc Surg, 2020.
, “Prediction of type 2 diabetes risk in people with non-diabetic hyperglycaemia: model derivation and validation using UK primary care data”, BMJ Open, vol. 10, p. e037937, 2020.
, “Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity”, Circ Heart Fail, vol. 13, p. e006472, 2020.
, , , “20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study”, Lancet Public Health, vol. 4, pp. e406-e420, 2019.
, “Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study”, Nutr Metab Cardiovasc Dis, vol. 29, pp. 481-488, 2019.
, , “Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe”, JAMA Netw Open, vol. 1, p. e185554, 2018.
, “Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink”, BMC Med, vol. 16, p. 116, 2018.
, “SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL”, J Am Coll Cardiol, vol. 71, pp. 2497-2506, 2018.
, “Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes”, Diabetes Care, vol. 41, pp. 2096-2104, 2018.
, “Changes in HbA1c and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice.”, Diabetologia., vol. 60, p. S301, 2017.
, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo”, Circulation, vol. 136, pp. 249-259, 2017.
, “Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study”, BMJ Open, vol. 7, p. e013851, 2017.
, “Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes”, J Diabetes, vol. 8, pp. 354-62, 2016.
, “Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin”, Diabetes Obes Metab, vol. 18, pp. 401-9, 2016.
, “Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK”, BMJ Open, vol. 6, p. e011805, 2016.
, “Impact of the National Health Service Health Check on cardiovascular disease risk: a difference-in-differences matching analysis”, Cmaj, vol. 188, pp. E228-38, 2016.
, “An algorithm to improve diagnostic accuracy in diabetes in computerised problem orientated medical records (POMR) compared with an established algorithm developed in episode orientated records (EOMR)”, J Innov Health Inform, vol. 22, pp. 255-64, 2015.
, “Coverage of a national cardiovascular risk assessment and management programme (NHS Health Check): Retrospective database study”, Prev Med, vol. 78, pp. 1-8, 2015.
, “Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes”, Cardiovasc Diabetol, vol. 14, p. 100, 2015.
, “Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study”, Diabetes Care, vol. 38, pp. 316-22, 2015.
, “Obesity paradox in people newly diagnosed with type 2 diabetes with and without prior cardiovascular disease”, Diabetes Obes Metab, vol. 16, pp. 317-25, 2014.
, “Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people”, Diabetes Care, vol. 36, pp. 3411-7, 2013.
, ,
,
“New cases of diabetes mellitus in England and Wales, 1994-1998: database study”, Public Health, vol. 119, pp. 892-9, 2005.
, “Prevalence of diagnosed diabetes mellitus in general practice in England and Wales, 1994 to 1998”, Health Stat Q, pp. 5-13, 2002.
,